ProfileGDS5678 / 1453107_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 55% 61% 64% 62% 64% 54% 56% 60% 53% 70% 62% 59% 69% 65% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.4328455
GSM967853U87-EV human glioblastoma xenograft - Control 23.6298361
GSM967854U87-EV human glioblastoma xenograft - Control 33.8474264
GSM967855U87-EV human glioblastoma xenograft - Control 43.6511262
GSM967856U87-EV human glioblastoma xenograft - Control 53.7860564
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.441354
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.4848856
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.6145760
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.2839853
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.4180270
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.6993362
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.4892559
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.2377269
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.9338365